| 000 | 00958 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250517161327.0 | ||
| 264 | 0 | _c20190702 | |
| 008 | 201907s 0 0 eng d | ||
| 022 | _a1468-4357 | ||
| 024 | 7 |
_a10.1093/biostatistics/kxx019 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLo, Andrew W | |
| 245 | 0 | 0 |
_aDiscussion: New directions for the FDA in the 21st century. _h[electronic resource] |
| 260 |
_bBiostatistics (Oxford, England) _c07 2017 |
||
| 300 |
_a404-407 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aDrug Approval |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPatient Preference |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aUnited States Food and Drug Administration _xlegislation & jurisprudence |
| 773 | 0 |
_tBiostatistics (Oxford, England) _gvol. 18 _gno. 3 _gp. 404-407 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/biostatistics/kxx019 _zAvailable from publisher's website |
| 999 |
_c27295725 _d27295725 |
||